Core C is a new core in our submission that offers much needed expertise in pathology and virology to Projects 2 and 3 and to Core B. The services, expertise and reagents provided by this core helps Projects 2 and 3 and Core B to address criticisms and concerns that were raised by the review panel. Moreover, this core provides some key services and reagents originally provided by former project 2 that has been deleted in this resubmission. This core will 1). provide diagnostic pathology for the identification of hamster, mouse and human malignant mesotheliomas (MM) and derived cell lines;2). provide virology expertise and reagents to Projects 2 and 3;3). Characterize primary human mesothelial cell cultures and obtain primary hamster mesothelial cell cultures;4). provide human cell lines transformed by SV40, SV40 small tag mutants and asbestos - alone or in combination;5). provide hamster MM and derived cell lines induced by crocidolite asbestos, SV40, SV40 small tag mutant plus crocidolite;6). produce and provide similar in vitro and vivo models using chrysotile asbestos;7). using immunohistochemistry, in situ hibridization and laser capture microdisection followed by Real Time and RT - PCR analyze gene pathways studied in Project 2 and 3 in animal and human MM tumors induced by SV40 alone, SV40 small tag mutant plus crocidolite or chrysotile, or by crocidolite or chrysotile alone;8). provide independent SV40 testing of human MM biopsies using immunoprecipitation, Western blotting and immunohistochemistry.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA114047-04
Application #
7933988
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$280,062
Indirect Cost
Name
University of Hawaii
Department
Type
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Napolitano, A; Pellegrini, L; Dey, A et al. (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35:1996-2002
Nasu, Masaki; Emi, Mitsuru; Pastorino, Sandra et al. (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565-76
Bononi, Angela; Napolitano, Andrea; Pass, Harvey I et al. (2015) Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med 9:633-54
Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol 10:731-7
Baumann, Francine; Flores, Erin; Napolitano, Andrea et al. (2015) Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36:76-81
Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) Reply to ""No Increased Risk for Mesothelioma in Relation to Natural-Occurring Asbestos in Southern Nevada"". J Thorac Oncol 10:e64-5
Deng, Xu-Bin; Xiao, Li; Wu, Yue et al. (2015) Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. Int J Cancer 137:481-90
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Yang, H; Pellegrini, L; Napolitano, A et al. (2015) Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 6:e1786
Menges, Craig W; Kadariya, Yuwaraj; Altomare, Deborah et al. (2014) Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 74:1261-1271

Showing the most recent 10 out of 52 publications